Artificial Intelligence-Enabled ECG: a Modern Lens on an Old Technology


Purpose of Review

To (i) review the concept of artificial intelligence (AI); (ii) summarize recent developments in artificial intelligence-enabled electrocardiogram (AI-ECG); (iii) address notable inherent limitations and challenges of AI-ECG; and (iv) discuss the future direction of the field.

Recent Findings

Advancements in machine learning and computing methods have led to application of AI-ECG and potential new applications to patient care. Further study is needed to verify previous findings in diverse populations as well as begin to confront the limitations needed for clinical implementation.


Nearly one century after the Nobel Prize was awarded to Willem Einthoven for demonstrating that an electrocardiogram (ECG) could record the electrical signature of the heart, the ECG remains one of the most important diagnostic tests in modern medicine. We now stand at the edge of true ECG innovation. Simultaneous advancements in computing power, wireless technology, digitized data availability, and machine learning have led to the birth of AI-ECG algorithms with novel capabilities and real potential for clinical application. AI has the potential to improve diagnostic accuracy and efficiency by providing fully automated, unbiased, and unambiguous ECG analysis along with promising new findings that may unlock new value in the ECG. These breakthroughs may cause a paradigm shift in clinical workflow as well as patient monitoring and management.

This is a preview of subscription content, log in to check access.

Fig. 1


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Taback L, Marden E, Mason HL, Pipberger HV. Digital recording of electrocardiographic data for analysis by a digital computer. IRE Trans Med Electron. 1959;6:167–71.

    Google Scholar 

  2. 2.

    Caceres CA, Steinberg CA, Abraham S, Carbery WJ, Mcbride JM, Tolles WE, et al. Computer extraction of electrocardiographic parameters. Circulation. 1962;25:356–62.

    CAS  PubMed  Google Scholar 

  3. 3.

    Schlapfer J, Wellens HJ. Computer-interpreted electrocardiograms: benefits and limitations. J Am Coll Cardiol. 2017;70:1183–92.

    PubMed  Google Scholar 

  4. 4.

    Shah AP, Rubin SA. Errors in the computerized electrocardiogram interpretation of cardiac rhythm. J Electrocardiol. 2007;40:385–90.

    PubMed  Google Scholar 

  5. 5.

    Guglin ME, Thatai D. Common errors in computer electrocardiogram interpretation. Int J Cardiol. 2006;106:232–7.

    PubMed  Google Scholar 

  6. 6.

    Poon K, Okin PM, Kligfield P. Diagnostic performance of a computer-based. ECG rhythm algorithm. J Electrocardiol. 2005;38:235–8.

    PubMed  Google Scholar 

  7. 7.

    Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia NAY. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Smith SW, Walsh B, Grauer K, Wang K, Rapin J, Li J, et al. A deep neural network learning algorithm outperforms a conventional algorithm for emergency department electrocardiogram interpretation. J Electrocardiol. 2019;52:88–95.

    PubMed  Google Scholar 

  9. 9.

    Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–17.

    PubMed  Google Scholar 

  10. 10.

    Smith SW, Rapin J, Li J, Fleureau Y, Fennell W, Walsh BM, et al. A deep neural network for 12-lead electrocardiogram interpretation outperforms conventional algorithm, and its physician overread, in the diagnosis of atrial fibrillation. IJC Heart Vasc. 2019;25:100423.

    Google Scholar 

  11. 11.

    Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.

    PubMed  Google Scholar 

  12. 12.

    Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–82.

    PubMed  Google Scholar 

  13. 13.

    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial-infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.

    CAS  Google Scholar 

  14. 14.

    Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288:1252–9.

    CAS  PubMed  Google Scholar 

  15. 15.

    Davenport C, Cheng EY, Kwok YT, Lai AH, Wakabayashi T, Hyde C, et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract. 2006;56:48–56.

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J. 2008;38:101–13.

    CAS  PubMed  Google Scholar 

  17. 17.

    Olesen LL, Andersen A. ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Fail. 2016;3:44–52.

    PubMed  Google Scholar 

  18. 18.

    Latour-Perez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail. 2006;8:390–9.

    CAS  PubMed  Google Scholar 

  19. 19.

    Betti I, Castelli G, Barchielli A, Belgini C, Boscherini V, De Luca L, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009;15:377–84.

    CAS  PubMed  Google Scholar 

  20. 20.

    Atherton JJ. Screening for left ventricular systolic dysfunction: is imaging a solution? JACC Cardiovasc Imaging. 2010;3:421–8.

    PubMed  Google Scholar 

  21. 21.

    •• Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019;25:70–4 Findings demonstrate the ability an AI-ECG algorithm to detect LVSD.

    CAS  PubMed  Google Scholar 

  22. 22.

    Mayo Clinic. ECG AI-Guided Screening for Low Ejection Fraction (EAGLE) ( Identifier NCT04000087). 2019. Retrieved from

  23. 23.

    Yao X, McCoy RG, Friedman PA, Shah ND, Barry BA, Behnken EM, et al. ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): rationale and design of a pragmatic cluster randomization trail. Am Heart J. 2020;219:31–6.

    PubMed  Google Scholar 

  24. 24.

    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death the Framingham heart study. Circulation. 1998;98(10):946–52.

    CAS  PubMed  Google Scholar 

  25. 25.

    Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.

    PubMed  Google Scholar 

  26. 26.

    Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015;14(9):903–13.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Sahay S, Nombela-Franco L, Rodes-Cabau J, Jimenez-Quevedo P, Salinas P, Biagioni C, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomized trials. Heart. 2017;103(2):139–47.

    CAS  PubMed  Google Scholar 

  28. 28.

    Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.

    CAS  PubMed  Google Scholar 

  29. 29.

    Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.

    CAS  PubMed  Google Scholar 

  30. 30.

    Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019;394(10201):861–7.

    PubMed  Google Scholar 

  31. 31.

    Kashou AH, Rabinstein AA, Attia IZ, Asirvatham SJ, Gersh BJ, Friedman PA, et al. Recurrent cryptogenic stroke: a potential role for an artificial intelligenceenabled electrocardiogram? HeartRhythm Case Rep. 2020;6:202–5.

  32. 32.

    Malik M, Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM. QT/RR curvatures in healthy subjects: sex differences and covariates. Am J Physiol Heart Circ Physiol. 2013;305:H1798–806.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Salama G, Bett GC. Sex differences in the mechanisms underlying long QT syndrome. Am J Physiol Heart Circ Physiol. 2014;307:H640–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Ball RL, Feiveson AH, Schlegel TT, Starc V, Dabney AR. Predicting “heart age” using electrocardiography. J Pers Med. 2014;4:65–78.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Attia ZI, Friedman PA, Noseworthy PA, Lopez-Jimenez F, Ladewig DJ, Satam G, et al. Age and sex estimation using artificial intelligence from standard 12-lead ECGs. Circ Arrhythm Electrophysiol. 2019;12:e007284.

    PubMed  Google Scholar 

  36. 36.

    Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156–62.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157–64.

    CAS  PubMed  Google Scholar 

  38. 38.

    Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373:60–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Dillon JJ, DeSimone CV, Sapir Y, Somers VK, Dugan JL, Bruce CJ, et al. Noninvasive potassium determination using a mathematically processed ECG: proof of concept for a novel “blood-less, blood test”. J Electrocardiol. 2015;48(1):12–8.

    PubMed  Google Scholar 

  40. 40.

    Attia ZI, DeSimone CV, Dillon JJ, Sapir Y, Somers VK, Dugan JL, et al. Novel bloodless potassium determination using a signal-processed single-lead ECG. J Am Heart Assoc. 2016;5(1):e002746.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Galloway CD, Valys AV, Sheribati JB, Treiman DL, Petterson FL, Gundotra VP, et al. Development and validation of a deep-learning model to screen for hyperkalemia from the electrocardiogram. JAMA Cardiol. 2019;4(5):428–36.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.

    PubMed  Google Scholar 

  43. 43.

    Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study: Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–9.

    CAS  PubMed  Google Scholar 

  44. 44.

    Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of sudden death in U.S. college athletes. J Am Coll Cardiol. 2014;63:1636–43.

    PubMed  Google Scholar 

  45. 45.

    McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54:229–33.

    PubMed  Google Scholar 

  46. 46.

    Pelliccia A, Maron BJ, Culasso F, di Paolo FM, Spataro A, Biffi A, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation. 2000;102:278–84.

    CAS  PubMed  Google Scholar 

  47. 47.

    Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, et al. Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2014;64:1479–514.

    PubMed  Google Scholar 

  48. 48.

    Ko WY, Siontis KC, Attia ZI, Carter RE, Kapa S, Ommen SR, et al. Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram. J Am Coll Cardiol. 2020;75:722–33.

    PubMed  Google Scholar 

  49. 49.

    Noseworthy PA, Attia ZI, Brewer LC, Hayes SN, Yao X, Kapa S, et al. Assessing and mitigating bias in medical artificial intelligence: the effects of race and ethnicity on a deep learning model for ECG analysis. Circ Arrhythm Electrophysiol. 2020;13(3):e007988.

    PubMed  Google Scholar 

  50. 50.

    Rudiger A, Hellermann R, Mukherjee R, Follath F, Turina J. Electrocardiographic artifacts due to electrode misplacement and their frequency in different clinical settings. Am J Emerg Med. 2007;25:174–8.

    PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Peter A. Noseworthy.

Ethics declarations

Conflict of Interest

Anthony H. Kashou and Adam M. May declare that they have no conflict of interest. Peter A. Noseworthy has a potential equity financial interest in AliveCor although he has received no payments from Alivecor. In addition, Dr. Noseworthy has two pending patents (US2019/033678 and 62/751,395).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kashou, A.H., May, A.M. & Noseworthy, P.A. Artificial Intelligence-Enabled ECG: a Modern Lens on an Old Technology. Curr Cardiol Rep 22, 57 (2020).

Download citation


  • Electrocardiogram
  • Artificial intelligence
  • Machine learning
  • Deep learning
  • Convolutional neural network